ProPhase Labs, Inc. (PRPH): Capital Expenditures
$0
Year ended 2025-12-31
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-06-01, From 2025-01-01 |
| 2024-12-31 | $906.0K | -56.5% | 2026-06-01, From 2024-01-01 |
| 2023-12-31 | $2.08M | n/c | 2025-04-01, From 2023-01-01 |
| 2022-12-31 | $3.92M | -7.4% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $4.23M | +150.5% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $1.69M | +640.8% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $228.0K | +62.9% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $140.0K | -32.7% | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | $208.0K | -68.0% | 2019-03-26, From 2017-01-01 |
| 2016-12-31 | $651.0K | -9.3% | 2018-08-20, From 2016-01-01 |
| 2015-12-31 | $718.0K | +130.1% | 2018-08-20, From 2015-01-01 |
| 2014-12-31 | $312.0K | -29.4% | 2017-02-24, From 2014-01-01 |
| 2013-12-31 | $442.0K | +42.6% | 2016-03-29, From 2013-01-01 |
| 2012-12-31 | $310.0K | +3.3% | 2015-03-27, From 2012-01-01 |
| 2011-12-31 | $300.0K | +96.1% | 2014-03-27, From 2011-01-01 |
| 2010-12-31 | $153.0K | -26.4% | 2013-03-28, From 2010-01-01 |
| 2009-12-31 | $208.0K | n/a | 2012-03-07, From 2009-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $0 | -100.0% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $59.3K | +54.4% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $123.6K | n/a |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $279.0K | -36.7% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $518.0K | -97.1% |
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $165.0K | -67.7% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $5.45M | -40.0% |
| Immunome Inc. (IMNM) | 2025-12-31 | $9.69M | +35.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $552.0K | -66.6% |
Compare PRPH, CPHI, ENSC, CAMP side by side · Screen every company in Pharmaceutical Preparations ↗